Generic substitution

British Journal of Clinical Pharmacology

Volumn 72, Issue 5, 2011, Pages 731-732

  Posner, John ^a   Griffin, John P ^b  

^a John Posner Consulting   (United Kingdom)

^b Asklepieion Consultancy Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; GENERIC DRUG; GENERIC SUBSTITUTION; RANITIDINE; UNCLASSIFIED DRUG;

BIOAVAILABILITY; BIOEQUIVALENCE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; NOTE; PRESCRIPTION; PRIORITY JOURNAL; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; DRUG SUBSTITUTION; DRUGS, GENERIC; GREAT BRITAIN; HUMANS;

EID: 80053914891     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.03920.x     Document Type: Note

References (5)

1. Informal Working Group on Effective Prescribing. Report to the Secretary of State for Social Services. London: DHSS, 1983. (Greenfield Report).
2. Department for Business Innovation and Skills. The pharmaceutical price regulation scheme. June 2009. Available at (last accessed 16 February 2011).
3. EMEA/CPMP. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2005. EMEA/CPMP/42832/05.
4. EMA/CPMP. Guideline on similar biological medicinal products containing monoclonal antibodies. 2010. EMA/CHMP/BMWP/403543/2010.
5. EMA/CPMP. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. 2010. EMA/CHMP/BMWP/86289/2010.